Anti-C1q antibodies are highly prevalent among patients with IgG4-RD, particularly those with renal and skin manifestations.

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis optica (NMO), in a pivotal clinical trial. Just 10% of ...

Percentages of children with peanut allergy who responded to treatment with the VP250 VIASKIN Peanut patch from DBV ...

The systemic disease of which AIP is a part has been called IgG4-related systemic diseases. AIP mimics pancreatic cancer and it is critically important to distinguish between the two diseases.

The properties of the different IgG isotypes should be considered in developing therapeutic antibodies. To address this problem, antibody engineers introduced a serine-to-proline substitution that ...

Children with peanut allergy using the Viaskin peanut patch (VP250) may experience greater clinical benefit with long-term use.